Core Insights - JCDecaux SE has signed a share purchase agreement to sell 325,519 shares of APG|SGA, representing 10.85% of its share capital to NZZ [1][2] - The transaction requires the introduction of an opting-up provision, which was approved by APG|SGA shareholders, ensuring no mandatory offer by NZZ is triggered [2] - The completion of the sale is anticipated in Q2 2026, pending antitrust approvals [2] Financial Impact - Post-transaction, JCDecaux's stake in APG|SGA will decrease to approximately 5.6% [3] - The deal is expected to generate cash proceeds of around 71 million CHF (approximately 76 million EUR) before transaction costs [3] Company Overview - JCDecaux is the leading outdoor advertising company globally, with 2024 revenue projected at €3,935.3 million and H1 2025 revenue at €1,868.3 million [7] - The company reaches a daily audience of 850 million across more than 80 countries, operating 1,091,811 advertising panels [7] - JCDecaux is recognized for its sustainability efforts, having joined the Euronext Paris CAC® SBT 1.5° index and achieving high ratings in various sustainability assessments [7]

Company Overview - ZyVersa Therapeutics, Inc. is a clinical stage specialty biopharmaceutical company focused on developing first-in-class drugs for renal and inflammatory diseases with significant unmet medical needs [5] - The company is advancing a therapeutic development pipeline that includes Cholesterol Efflux Mediator™ VAR 200 for kidney diseases and Inflammasome ASC Inhibitor IC 100 for inflammatory diseases [5] Share Purchase Agreement (SPA) - ZyVersa has entered into a share purchase agreement with Williamsburg Venture Holdings, allowing the company to sell up to $10 million worth of common stock over a 24-month period [3] - The SPA provides ZyVersa with flexibility in planning the timing and amount of equity sales, aiming to minimize dilution while sustaining shareholder value [2][3] - ZyVersa retains control over the timing and amount of all common stock sales, with no associated warrants or derivatives [3] Market Potential - The global drug market for kidney diseases was valued at $18 billion in 2024 and is projected to reach $30 billion by 2034 [1]